Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYS6043 + bevacizumab
- Development stage
- Phase 2
- Lead developer
- Suzhou Xinnuowei Pharmaceutical Technology
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SYS6043 + bevacizumab is an investigational combination regimen being developed by CSPC Megalith Biopharmaceutical (a subsidiary of CSPC Pharmaceutical Group) and its subsidiary Conjupro Biotherapeutics for the treatment of advanced solid tumors, including gynecologic cancers such as platinum-resistant ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. The regimen combines SYS6043, a humanized monoclonal antibody-drug conjugate (ADC) targeting B7-H3 (CD276) conjugated to a DNA topoisomerase I inhibitor payload, with bevacizumab, a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A). By combining the targeted cytotoxic delivery of the B7-H3 ADC with the anti-angiogenic effects of bevacizumab, the combination aims to achieve synergistic antitumor efficacy. The combination is currently being evaluated in Phase I/II clinical trials.
- Other names
- bevacizumab + SYS-6043bevacizumab + SYS6043SYS-6043 + bevacizumabSYS6043 + bevacizumab
02
Targets
B7-H3VEGFA (Vascular endothelial growth factor A)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on SYS6043 + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYS6043 + bevacizumab.